Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Table 3
Comparison of the changes in in insulin dosage and clinical features from before to after treatment between the CSII and CSII + Sig groups.
Characteristic
Group
value
CSII
CSII + Sig
Δdosage of insulin (U)
4.14 ± 8.59
−2.02 ± 7.50
<0.01
Δbasal insulin dose (U)
1.27 ± 4.59
0.38 ± 4.24
0.44
Δbolus insulin dose (U)
2.87 ± 5.81
−2.40 ± 3.65
<0.01
Δbasal/bolus ratio
0.05 ± 0.89
0.22 ± 0.20
0.31
Δweight (kg)
−0.04 ± 1.38
−0.54 ± 1.18
0.14
ΔBMI (kg/m2)
−0.02 ± 0.51
−0.19 ± 0.41
0.15
Time to achieve euglycemia (h)
127.92 ± 27.60
92.88 ± 18.72
<0.01
ΔGA (%)
−4.82 ± 2.75
−8.02 ± 2.90
<0.01
ΔFPG (mmol/L)
−3.85 ± 1.39
−4.39 ± 1.23
0.12
ΔPPG (mmol/L)
−4.20 ± 2.32
−6.45 ± 3.13
<0.01
ΔFC-P (ng/mL)
0.09 ± 0.37
0.21 ± 0.54
0.29
ΔPC-P (ng/mL)
1.46 ± 1.26
1.76 ± 1.57
0.41
ΔCPI
0.63 ± 0.32
0.84 ± 0.42
0.03
ΔSUIT
1.64 ± 0.86
2.20 ± 1.10
0.03
ΔTC (mmol/L)
−0.35 ± 0.40
−0.39 ± 0.65
0.74
ΔHDL-C (mmol/L)
−0.04 ± 0.19
−0.05 ± 0.16
0.82
ΔLDL-C (mmol/L)
−0.12 ± 0.29
−0.22 ± 0.51
0.40
ΔTg (mmol/L)
−0.13 ± 0.20
−0.29 ± 0.50
0.10
Note: Δ: change from before treatment to after. Data are presented as the means ± SD. Paired -tests were employed.
